Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)

Subscribe to Selected New Research on Fluorodeoxyglucose F18

1669 relevant articles (47 outcomes, 274 trials/studies) found for this Drug

Description: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)

Also Known As:

Fludeoxyglucose F 18; 18F-FDG; Fluorine-18-fluorodeoxyglucose; Fluorodeoxyglucose F 18; 2 Fluoro 2 deoxy D glucose; 2 Fluoro 2 deoxyglucose; F 18, Fludeoxyglucose; F 18, Fluorodeoxyglucose; F18, Fluorodeoxyglucose; Fluorine 18 fluorodeoxyglucose; Fluorodeoxyglucose, 18F; 18F Fluorodeoxyglucose; 18FDG; 2-Fluoro-2-deoxy-D-glucose; 2-Fluoro-2-deoxyglucose

Relationship Network

Drug Context: Research Results

Carbohydrates: 2949

Deoxy Sugars: 2

Deoxyglucose: 1628

Fluorodeoxyglucose F18: 1669

Experts

1.	Yen, Tzu-Chen: 14 articles (10/2007 - 10/2003)
2.	Alavi, Abass: 13 articles (04/2008 - 06/2004)
3.	Fanti, Stefano: 12 articles (07/2008 - 04/2004)
4.	Nanni, Cristina: 11 articles (07/2008 - 04/2004)
5.	Castellucci, Paolo: 10 articles (07/2008 - 04/2004)
6.	Rubello, Domenico: 10 articles (07/2008 - 07/2005)
7.	Larson, Steven M: 9 articles (04/2008 - 01/2002)
8.	Kim, Byung-Tae: 9 articles (01/2008 - 11/2004)
9.	Chan, Sheng-Chieh: 9 articles (10/2007 - 10/2004)
10.	Ng, Shu-Hang: 9 articles (10/2007 - 10/2004)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2008 - "CONCLUSION: The diagnostic accuracy of 18F-FDG PET/CT was shown to be nearly equal to ultrasound, and considering their limited sensitivities, the high radiation exposure by 18F-FDG PET/CT and also costs of the examination, it is likely that AUS will be more cost-effective in detecting massive axillary tumor burden" 05/01/1997 - "With MMC and CDDP, size reduction became significant on Days 8 or 11, whereas 18F-FDG tumor uptake had already been decreased on Days 3 or 7. CONCLUSION: Fluorine-18-FDG uptake decreases in parallel to the efficacy of anticancer agents and correlates with subsequent morphologic changes" 04/01/2008 - "CONCLUSION: The present study indicates that 11C-Gly-Sar is a promising tumor-imaging agent and is superior to 18F-FDG for distinguishing between tumors and inflammatory tissue" 10/01/2000 - "Standardized uptake value (SUV) for [F-18]fluorodeoxyglucose (FDG) studies that is commonly used to differentiate malignant from benign tumors and to assess the efficacy of therapy is reviewed as a simplified calculation of the more general modeling approach" 02/19/2005 - "The prognostic information available through 18F-FDG PET is superior to that of conventional imaging for many cancers" Order ALL the reference details at left...
2.	Neoplasm Metastasis (Metastasis) 05/01/2005 - "CONCLUSION: 18F-FDG PET is superior to MRI in identifying lower neck nodal metastasis of NPC" 05/01/2003 - "CONCLUSION: Whenever 18F-FDG PET and LAG are performed in the same patient to assess the extent of lymph-node metastases, LAG should always be done after the 18F-FDG PET study to obviate false-positive results." 02/01/2006 - "The main objective of this study is to evaluate positron emission tomography (PET) using fluorine-18-labeled fluorodeoxyglucose ([18F]FDG) and conventional skeletal scintigraphy (SS) for detecting bone metastasis at initial staging" 10/01/2004 - "CONCLUSIONS: This preliminary study suggested that 18F-FDG PET could provide additional information and contribute to the management of HCC patients suspected of having extrahepatic metastases." 10/01/2004 - "The aim of this study was to evaluate the usefulness of 18F-FDG PET for the detection of extrahepatic metastases from HCC" Order ALL the reference details at left...
3.	Breast Neoplasms (Breast Cancer) 03/01/2007 - "The aim of this study is to assess the diagnostic value of positron emission tomography (PET) utilizing [18F]2-fluoro-2-deoxy-D-glucose (FDG) in the axillary staging of breast cancer" 06/01/2004 - "In this review the findings of response monitoring studies in breast cancer, using [(18)F]2-fluoro-2-deoxy-D-glucose (FDG) and positron emission tomography (PET), are summarised" 10/10/2008 - "Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures." 08/01/2008 - "CONCLUSION: Our data suggest that a whole-body 18F-FDG PET/CT mammography protocol may be used for staging breast cancer in a single session" 08/01/2008 - "Our objective was to compare the diagnostic accuracy of an all-in-one protocol of whole-body 18F-FDG PET/CT and integrated 18F-FDG PET/CT mammography with the diagnostic accuracy of a multimodality algorithm for initial breast cancer staging" Order ALL the reference details at left...
4.	Small Cell Carcinoma (Small Cell Lung Cancer) 01/01/2007 - "Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT." 06/01/2007 - "Preliminary study of 18F-FDG PET-CT in defining lymph node radiation target volume for non-small-cell lung cancer patients]" 10/01/2006 - "OBJECTIVE: The purpose of this study was to report the prevalence of abnormalities that do not show increased 18F-FDG uptake on the CT component of integrated PET/CT in patients with non-small cell lung cancer" 10/01/2006 - "The American College of Surgeons Oncology Group recently completed a trial evaluating the role of PET with 18F-FDG in patients with documented or suspected non-small cell lung cancer" 04/20/2006 - "Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study." Order ALL the reference details at left...
5.	Lung Neoplasms (Lung Cancer) 10/01/2004 - "The goal of this study was to assess the value of hybrid imaging using a combined PET/CT device with 18F-FDG in the diagnosis and clinical management of suspected recurrent lung cancer" 01/01/2003 - "The aim of this study was to evaluate [18F]fluorodeoxyglucose ( F-FDG) imaging of recurrent or inoperable lung cancer using a hybrid positron emission tomography (PET) device of the third generation" 07/01/2000 - "PURPOSE: The purpose of this study was to clarify the validity of (99m)Tc-tetrofosmin SPECT (TF-SPECT) in the evaluation of lung cancer in comparison with [18F]fluorodeoxyglucose ([18F]FDG-PET)" 11/01/2008 - "PURPOSE: To compare 18F-FDG PET/CT with standard contrast-enhanced CT for the diagnosis and staging of lung neoplasms eligible for surgical resection" 10/01/2008 - "Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Ro 07-0741
3.	Ammonia
4.	methionine methyl ester
5.	Biological Markers (Surrogate Marker)
6.	Biological Tumor Markers (Tumor Markers)
7.	Ganciclovir (Cytovene)
8.	Indicators and Reagents (Reagents)
9.	fialuridine
10.	methylene diphosphonate

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Electrodes (Electrode)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Hip Replacement Arthroplasty (Total Hip Replacement)
5.	Heterologous Transplantation (Xenotransplantation)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18531 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>